Can CVS Sustain Pharmacy & Consumer Wellness Gains Through Year-End?

CVS Health's Pharmacy and Consumer Wellness (PCW) segment reported an 11.1% year-over-year revenue increase in Q1 2025, driven by seasonal trends and a favorable drug mix, including high-demand GLP-1 medications, further bolstered by its inclusion in Novo Nordisk's NovoCare network for Wegovy access. The segment is poised for improved results from the full implementation of its CostVantage reimbursement model and maintained a strong 27.6% retail pharmacy script share despite completing 900 store closures. While facing ongoing pharmacy reimbursement pressure and potential consumer softening, CVS shares have rallied 18.9% over the past year, outperforming the industry and trading at a discounted forward earnings multiple of 10.18X.

Analysis

CVS Health's Pharmacy and Consumer Wellness (PCW) segment demonstrated robust performance in Q1 2025, with an 11.1% year-over-year revenue increase. This growth was driven by a combination of seasonal factors and, more significantly, structural tailwinds including a favorable drug mix led by high-demand GLP-1 medications. The company's strategic positioning is enhanced by its inclusion in Novo Nordisk's NovoCare network, expanding access to Wegovy, and the full implementation of its CostVantage reimbursement model, which is expected to improve future results by rationalizing pricing. Operationally, CVS has shown impressive execution by increasing its retail pharmacy script share by nearly 70 basis points to 27.6%, despite completing a 900-store closure plan. This indicates strong customer retention and an effective omnichannel strategy. While a key competitor, Walmart, also reported strong health and wellness sales growth in the high teens, CVS's stock performance has significantly outpaced the industry, rallying 18.9% over the past year against the sector's 14.6% decline. Despite this rally, the stock trades at a discounted forward P/E multiple of 10.18X compared to the industry average of 14.07X. However, persistent pharmacy reimbursement pressure and potential softening in the consumer environment remain notable headwinds to monitor.

Key Decisions for Investors

• Given the strong revenue growth, market share gains despite a smaller store footprint, and a discounted forward P/E of 10.18X, investors may consider the stock favorably positioned relative to its industry.
• Investors should monitor the impact of the new CostVantage model on segment profitability and track prescription volumes, particularly for high-value GLP-1 drugs, as these are critical drivers for sustaining momentum.
• It is crucial to watch for external risks such as intensified pharmacy reimbursement pressures and any signs of a weakening consumer environment, which could present headwinds to the segment's growth.